Navigation Links
New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population
Date:9/1/2011

WASHINGTON, Sept. 1, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive.  The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.  

Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation. According to the FDA, the mutation is only present in 1-7% of people with NSCLC, primarily those diagnosed with adenocarcinoma.

"This is exciting news," said LCA President & CEO, Laurie Fenton Ambrose.  "Personalized medicine is where we are headed for lung cancer treatments.  This is one of the first steps towards identifying medications that help select populations of people.  We must continue to identify other mutations and find drugs that treat them to finally see cures for lung cancer." 

"I was enrolled in the phase I trial for this drug," said Linnea Duff, NH resident and longtime lung cancer survivor.  "At the time I began the trial, I was hoping to have my life extended for a few months. Instead, I got three more years to spend with my family and friends. In addition, because this was a targeted therapy, the side effects were minimal and my quality of life during this time has been remarkable."

Xalkori has shown a life changing response to lung cancer in those patients who are ALK positive.  Lung Cancer Alliance encourages lung cancer patients to discuss genetic testing options with their health care team.  

It is important to note that many genetic mutations have been identified but not all have drugs to target the mutations at this time. With continued focus from researchers and increased participation in clinical trials, more and more of these personalized therapies will become available.  

For more information about clinical trials, please call the Lung Cancer Clinical Trial Matching Service, 800-698-0931.

Lung Cancer Alliance is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.  Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance  

Media Contact:
Kay Cofrancesco
kay@lungcanceralliance.org
202-463-2080


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May Be Ineffective and Unsafe
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
4. Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. TandemHeart Approved for Expanded Reimbursement
6. Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List
7. Laureates Electronic Submission Gateway Approved
8. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
9. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
10. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
11. FDA Expands Approved Use For Carotid Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a ... first in a new class of photodynamic cosmetics (PDC). , Allumera® is the ... reduce outward signs of aging, and minimize the appearance of pores – all ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... signed an agreement to be the preferred physical therapy provider for Derby City ... them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent ... test score performance for the 2015-16 school year across Wisconsin’s public schools, charter ... it highlights important patterns in student test score performance, the report’s limited analyses ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Lake Park Dental ... by using Invisalign® in Lutz, FL. With the help of this highly-effective, ... aesthetics with fewer potential complications, more discretion and less pain. , Drs. Sarah ...
Breaking Medicine News(10 mins):